🚀
Enjoy a 7-Day Free Trial Thru May 03, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Calithera Biosciences Inc (OTCPK:CALA)
News
Calithera Biosciences Inc
OTCPK
:CALA (USA) Â
$ 0.02
0 (0%)
09:30 AM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 97.00K
Enterprise V:
$ -1.35M
Volume:
256.00
Avg Vol (2M):
1.23K
Warning! GuruFocus detected issues with CALA.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
256.00
Market Cap $:
97.00K
PE Ratio:
At Loss
Avg Vol (2M):
1.23K
Enterprise Value $:
-1.35M
PB Ratio:
0
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Calithera Biosciences Inc (OTCPK:CALA) Stock News, Headlines & Updates
Calithera Biosciences Inc Stock News from GuruFocus
Total 127
1
2
3
4
Jun 29, 2023
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
Marketwired
•
4:00pm
Feb 13, 2023
PRIMECAP Management's Top 5 Sells of the 4th Quarter
GuruFocus Research
•
2:00pm
Jan 09, 2023
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution
Stock market mentor
•
8:00am
Nov 08, 2022
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Value_Insider
•
4:01pm
Jul 14, 2022
Calithera Biosciences Announces 1-for-20 Reverse Stock Split
PurpleRose
•
12:30pm
Jul 13, 2022
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma
PurpleRose
•
3:35pm
Jul 09, 2022
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
GuruFocusNews
•
4:05pm
Jul 04, 2022
Calithera Biosciences Announces 1-for-20 Reverse Stock Split
GuruFocusNews
•
12:28pm
Jul 03, 2022
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma
GuruFocusNews
•
3:33pm
Jun 24, 2022
Calithera Biosciences Announces 1-for-20 Reverse Stock Split
GuruFocusNews
•
12:26pm
Jun 23, 2022
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma
GuruFocusNews
•
3:31pm
Jun 14, 2022
Calithera Biosciences Announces 1-for-20 Reverse Stock Split
GuruFocusNews
•
12:25pm
Jun 09, 2022
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
GuruFocusNews
•
4:04pm
May 30, 2022
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
GuruFocusNews
•
4:03pm
May 20, 2022
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
GuruFocusNews
•
4:03pm
Apr 08, 2022
Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds
GuruFocusNews
•
1:00pm
Mar 31, 2022
Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
GuruFocusNews
•
4:00pm
Mar 30, 2022
Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock
GuruFocusNews
•
1:00am
Mar 29, 2022
Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock
GuruFocusNews
•
4:00pm
Mar 24, 2022
Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022
GuruFocusNews
•
6:00am
Mar 08, 2022
Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting
GuruFocusNews
•
6:00am
Feb 16, 2022
Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
GuruFocusNews
•
6:00am
Nov 12, 2021
Calithera to Present at the 2021 Jefferies London Healthcare Conference
Don Li2
•
7:00am
Nov 05, 2021
Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer
Don Li2
•
6:00am
Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
Don Li2
•
6:00am
Nov 02, 2021
Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
Don Li2
•
4:01pm
Mar 10, 2021
Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021
Marketwired
•
7:02am
Mar 02, 2021
Calithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 Conference
Marketwired
•
7:02am
Feb 22, 2021
Calithera to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Marketwired
•
6:59am
Jan 12, 2021
INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium
Marketwired
•
7:00pm
Jan 11, 2021
INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium
GlobeNewswire
•
5:00pm
Jan 05, 2021
Calithera to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
Marketwired
•
7:00am
Jan 04, 2021
Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint
Marketwired
•
7:00am
Jan 01, 2021
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Marketwired
•
7:00pm
Dec 31, 2020
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
•
4:59pm
Dec 02, 2020
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marketwired
•
7:01am
Nov 11, 2020
Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1x1 Day
Marketwired
•
7:01am
Nov 09, 2020
Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting
Marketwired
•
7:02am
Nov 06, 2020
Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
Marketwired
•
7:00pm
Nov 04, 2020
Calithera Biosciences Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with palbociclib (IBRANCE®)
Marketwired
•
3:01pm
Total 127
1
2
3
4
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news